CA-ASM-GLOBAL
23.11.2022 02:58:42 CET | Business Wire | Press release
ASM Global, the world’s leading venue management company and producer of live experiences, has made history with the spectacular firework-laden inauguration ceremony of the 950,000-square-foot Exhibition World Bahrain—the largest exhibition centre in the Middle East.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005879/en/
Image courtesy of ASM Global
The Kingdom’s Exhibition World is one of the most contemporary such venues in the world. Its launch is a milestone in the Kingdom’s economic development and is expected to play a key role in advancing the economic competitiveness and positioning of Bahrain as a major global destination for regional and international conventions.
The venue joins ASM Global’s portfolio of more than 350 venues around the world and kicks off the company’s post-pandemic convention growth initiative.
ASM Global’s President and CEO Ron Bension said, “This moment is the culmination of our plan developed during the pandemic leveraging our belief that this part of the world would be the quickest to not only return to normal but move quickly to dramatically increase its convention and exhibition market share.
“We’re also looking forward to leveraging the widest network in the world within the MICE industry to create unique experiences built on years of expertise.”
The opening extravaganza was attended on behalf of His Majesty King Hamad bin Isa Al Khalifa, by His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister of Bahrain.
HRH Prince Salman bin Hamad highlighted the importance of competitiveness as a fundamental element of the kingdom’s economy, which has bolstered investments, promoted economic progress and created quality opportunities for citizens. He also noted that tourism remains a leading economic sector, adding that the sector's growth has been a key driver of the kingdom’s comprehensive development, led by His Majesty the King.
During the ceremony, Bahrain Tourism Minister H.E. Fatima Al Sairafi noted the kingdom’s longstanding history in being a destination linking the east and west for trade, which has furthered its position as a global tourist destination. She added that the inauguration of the venue reflects the kingdom’s commitment to expanding cross-sector development in line with Bahrain's sustainable development goals.
Exhibition World Bahrain is unique for its adaptable and flexible design, featuring 10 halls with a combined total of 95,000 sqm. The spectacular Grand Hall has a capacity of 4,000 seated guests and is supported by 94 meeting rooms as well as 25 F&B and retail outlets throughout the exhibition concourse. The centre’s spacious design enables it to host a number of events simultaneously, making it an attractive location for local, regional and international exhibitions, conventions, galas, weddings, concerts, sports, and live entertainment events.
Exhibition World Bahrain is owned by the Bahrain Tourism and Exhibitions Authority (BTEA), which plans to utilize ASM Global’s wider network within the MICE industry to create unique experiences built on years of expertise.
ASM Global APAC and Gulf Region Chairman and Chief Executive Harvey Lister AM congratulated BTEA on the inauguration of Exhibition World Bahrain, one of the Middle East’s largest exhibition and convention centres.
“ASM Global is proud to be working in partnership with BTEA helping to ensure Bahrain will be at the forefront of attracting tourism investment, international conventions and exhibitions and world-class live events to the Gulf region,” Lister said. “This iconic landmark venue will further position Bahrain as an international destination, helping to drive diversification of growth, benefiting the local economy and further enhancing the kingdom’s global standing.”
Exhibition World Bahrain General Manager Dr Debbie Kristiansen said she was extremely proud of her dedicated and committed team and their passion and determination to “give back” to the beautiful country of Bahrain, helping to create long-term legacies for the future. Dr Kristiansen highlighted the importance of mentoring and building the talent and skillset of young Bahrainis describing it as a “privilege.”
Following the grand opening, Exhibition World Bahrain immediately opened to the public with three concurrent events expected to see well over 100,000 visitors over the span of five days: Jewellery Arabia, the premier jewellery and watch show celebrating its 30th edition; Scent Arabia’s first-ever exhibition; and Cityscape, the region’s largest real estate summit and exhibition.
ASM Global’s network hosts 20,000 events and welcomes 165 million guests every year. Other flagship exhibition and convention centres in its portfolio include McCormick Place in Chicago; Moscone Center in San Francisco; ICC Sydney; Shenzhen World in China; and P&J Live in Aberdeen, U.K.
About ASM Global
ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibition centres, and performing arts venues. Follow us on Facebook, Instagram, Twitter and LinkedIn. asmglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom